



Vol. I No. I 1 February - 15 February

Company Spotlight

- **N30 Pharma** (Boulder) who is developing novel therapies for a variety of respiratory diseases (e.g. asthma, cystic fibrosis and chronic obstructive pulmonary disease) has successfully completed a Phase I study of their lead molecule N30-201.
- **Array Biopharma** (Boulder) provided a quarterly update call which included highlighting a strong cash position (approximately \$20M per quarter burn and approximately \$140M in cash on hand), along with a detailed review of their vast portfolio of wholly owned assets and partnered therapeutic portfolio.
- **Pharmion** (Boulder) received a letter indicating certain shareholder believe that the current structure of the deal with Celgene may be significantly undervaluing the potential of the therapeutic assets. *More info (here)*. Additionally, Pharmion who is co-developing with MethyIGene MGD01013 was granted orphan status designation for the molecule by both the FDA and their EU counterpart the European Medicines Agency.
- **Tapestry Pharmaceuticals** (Boulder) announced corporate preparation for a bankruptcy filing. Along with the SEC filing was an elimination of all staff sans core executives who will remain on to guide through the court proceedings, reorg efforts and sale of the company assets.
- **Chemizon** (Longmont) announced an agreement with the Korean Research Institute of Bioscience and Biotechnology to spin out a new TBD biotech company who will commercialize KRIBB intellectual property.
- **Quark Pharmaceuticals** (Boulder) is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates.
- **BioXel Pharma** (Lafayette) manufactures and markets taxane active pharmaceutical ingredients (APIs) and develops innovative new taxane-based chemotherapeutic drugs.

Financing Spotlight

- **Taligen Therapeutics** (Aurora) closed, who many to believe be the largest Series B financing in recent times, a \$65M round led by new investors Alta Partners and Clarus Ventures along with participation from previous investors Sanderling Ventures, Tango and High Country Venture.

Square Pegs

- **Coming soon:** The Colorado Life Science Index of public companies and CO related public companies to be benchmarked versus the NASDAQ Biotech Index
- **National Jewish Medical and Research Center** (Denver) has formed a strategic collaborative alliance with Siemens to incorporate genomic and proteomic based screens in patients with respiratory and cardiac disease. In addition, Siemens technology will power the NJMRC's new Advanced Biological Imaging Center. Finally, the third element of the agreement will include collaborative research efforts between the two entities based upon the combined diagnostic and imaging work.

Legislative Update

- Please see the attached weekly legislative report as provided by CBSA's lobbying team, Erin Silver and Danny Tomlinson.

**Advance Colorado Center • 1625 Broadway Suite 950 • Denver Colorado 80202
Phone: 303-592-4073 • Fax: 303-592-4081 • www.CoBioScience.com**